Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11878512 | 0.85 | SLC6A4 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1638815 | 0.81 | MAOA (0.43) | SLC6A2SLC6A4SLC6A3MAOAHTR2C | |
| SCHEMBL1639225 | 0.77 | SLC18A3 (0.43) | KDM1AMAOAMAOBKDM4E | |
| SCHEMBL451612 | 0.77 | SLC18A3 (0.43) | KDM1AMAOAMAOBKDM4E | |
| SCHEMBL1638075 | 0.77 | SLC18A3 (0.43) | KDM1AMAOAMAOBKDM4E | |
| SCHEMBL19580684 | 0.77 | L3MBTL1 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL22342845 | 0.77 | L3MBTL1 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL25973030 | 0.77 | L3MBTL1 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL31481180 | 0.77 | L3MBTL1 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL23992073 | 0.76 | NR1H4 (0.53) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805938-A1 | Bi- or tricyclic sterically hindered alkoxyamines and process for their preparation | BASF SE (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-8809533-B2 | Bi- or tricyclic sterically hindered alkoxyamines and process for their preparation | BASF SE (DE) | 2014-08-19 | — | — | US | disclosed |
| EP-2464628-B1 | BI - OR TRICYCLIC STERICALLY HINDERED ALKOXYAMINES AND PROCESS FOR THEIR PREPARATION | BASF SE (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-20140039100-A1 | BI - OR TRICYCLIC STERICALLY HINDERED ALKOXYAMINES AND PROCESS FOR THEIR PREPARATION | BASF SE (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8598369-B2 | Bi—or tricyclic sterically hindered alkoxyamines and process for their preparation | BASF SE (DE) | 2013-12-03 | — | — | US | disclosed |
| US-8492394-B2 | (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2013-07-23 | — | — | US | disclosed |
| EP-2057153-B1 | (3-ARYL-PIPERAZIN-1-YL) DERIVATIVES OF 6,7-DIALKOXYQUINAZOLINE, 6,7- DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | LUNDBECK & CO AS H (DK) | 2012-09-12 | — | — | EP | disclosed |
| US-20120178829-A1 | BI - OR TRICYCLIC STERICALLY HINDERED ALKOXYAMINES AND PROCESS FOR THEIR PREPARATION | BASF SE (DE) | 2012-07-12 | — | — | US | disclosed |
| EP-2464628-A1 | BI - OR TRICYCLIC STERICALLY HINDERED ALKOXYAMINES AND PROCESS FOR THEIR PREPARATION | BASF SE (DE) | 2012-06-20 | — | — | EP | disclosed |
| CN-102482217-A | Bicyclic or tricyclic sterically hindered alkoxyamines and process for their preparation | BASF SE | 2012-05-30 | — | — | CN | disclosed |
| US-20110098286-A1 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL-THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXY-QUINAZOLINE, 6,7-DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| WO-2011018384-A1 | BI - OR TRICYCLIC STERICALLY HINDERED ALKOXYAMINES AND PROCESS FOR THEIR PREPARATION | BASF SE (DE) | 2011-02-17 | — | — | WO | disclosed |
| EP-2057153-A1 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL- THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXYQUINAZOLINE, 6,7- DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | H.Lundbeck A/S (DK) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008006372-A1 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL- THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXYQUINAZOLINE, 6,7- DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | H. LUNDBECK A/S (DK) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098286-A1 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL-THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXY-QUINAZOLINE, 6,7-DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | PDE5A, PDE2A, PDE3A | SLC6A2 88/4885SLC6A4 158/4885SLC6A3 39/4885 |
| US-20120178829-A1 | BI - OR TRICYCLIC STERICALLY HINDERED ALKOXYAMINES AND PROCESS FOR THEIR PREPARATION | CAT, SCO2, GPX4 | SLC6A2 4043/4885SLC6A4 3142/4885SLC6A3 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.